Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of optic disc cupping and pallor of ocular hypertensives with timolol therapy

B Schwartz1, P Lavin, T Takamoto

  • 1Tufts University School of Medicine, Boston, Massachusetts, USA.

Acta Ophthalmologica Scandinavica. Supplement
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

Gynecologic oncology·2006
Same author

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

European journal of cancer (Oxford, England : 1990)·2006
Same author

How often should a port-A-cath be flushed?

Cancer investigation·2005
Same author

An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

Investigational new drugs·2005
Same author

HTS magnetometers for fetal magnetocardiography.

Neurology & clinical neurophysiology : NCN·2005
Same author

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same journal

Abstracts of the European Association for Vision and Eye Research Conference. 3-6 October 3-6, 2007. Portoroz, Slovenia.

Acta ophthalmologica Scandinavica. Supplement·2007
Same journal

Abstracts of the European Association for Vision and Eye Research Conference. October 4-7 2006. Vilamoura, Portugal.

Acta ophthalmologica Scandinavica. Supplement·2006
Same journal

Abstracts from the XXXVII Nordic Congress of Ophthalmology. June 17-20, 2006. Copenhagen, Denmark.

Acta ophthalmologica Scandinavica. Supplement·2006
Same journal

On the structural origin of refractive instability and corneal haze after excimer laser keratectomy for myopia.

Acta ophthalmologica Scandinavica. Supplement·2003
Same journal

Short-term results of a miniature draining implant for glaucoma in combined surgery with phacoemulsification.

Acta ophthalmologica Scandinavica. Supplement·2002
Same journal

Deep sclerectomy and viscocanalostomy: critical revision of the results obtained during the learning curve.

Acta ophthalmologica Scandinavica. Supplement·2002
See all related articles

Timolol eye drops significantly reduced optic disc cupping and pallor in ocular hypertensives, independent of intraocular pressure reduction. This suggests a direct therapeutic effect beyond lowering eye pressure.

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Pharmacology

Background:

  • Ocular hypertension is a risk factor for glaucoma.
  • Optic disc cupping and pallor are indicators of glaucomatous damage.
  • Timolol is a commonly used beta-blocker for lowering intraocular pressure.

Purpose of the Study:

  • To investigate the effect of timolol drops versus placebo on optic disc cupping and pallor in ocular hypertensives.
  • To determine if timolol has a direct impact on optic nerve head morphology.

Main Methods:

  • A double-masked, randomized clinical trial involving 37 ocular hypertensives.
  • Participants received either 0.5% timolol drops or placebo in both eyes.
  • Ocular pressure, optic disc cupping (photogrammetry), and pallor (computerized image analysis) were measured over 18-24 months.

Related Experiment Videos

Main Results:

  • No visual field loss occurred in any subject.
  • Timolol treatment led to a significant decrease in ocular pressure, optic disc cupping, and pallor compared to placebo.
  • Multivariate analyses showed no association between optic disc changes and ocular pressure levels or reduction.

Conclusions:

  • Timolol treatment is associated with reduced optic disc cupping and pallor in ocular hypertensives.
  • The observed effects of timolol on optic nerve head morphology may involve mechanisms independent of intraocular pressure reduction.